LEO Pharma’s Enstilar Receives the NMPA Approval for Plaque Psoriasis

Why It Matters

The approval gives LEO Pharma a foothold in China’s fast‑growing psoriasis market and offers clinicians a more convenient, high‑potency topical option, potentially shifting prescribing patterns away from existing ointments.

Key Takeaways

• Enstilar approved for adult plaque psoriasis in China
• Phase III trial (604 patients) showed superiority over Daivobet
• Aerosol foam applied once daily for up to four weeks
• Launch planned later this year, with long‑term maintenance option

Pulse Analysis

China’s psoriasis burden is substantial, with an estimated 7 million adults affected by plaque psoriasis, a condition that drives significant healthcare costs and quality‑of‑life concerns. Topical therapies dominate first‑line treatment, yet many patients struggle with ointments that can be greasy and difficult to apply. Recent regulatory reforms have accelerated the entry of foreign‑developed dermatologic products, creating a fertile market for innovative formulations that improve adherence and outcomes.

Enstilar’s aerosol foam pairs calcipotriene, a vitamin D analogue, with betamethasone dipropionate, a potent corticosteroid, delivering both agents in a non‑greasy, quick‑dry vehicle. In the pivotal Phase III study of 604 Chinese adults, once‑daily application for up to four weeks achieved higher clearance rates and faster symptom relief than the comparator Daivobet ointment, while meeting primary and secondary efficacy endpoints. The foam format enhances patient satisfaction, potentially translating into better long‑term disease control for responders who can transition to maintenance therapy.

For LEO Pharma, the NMPA approval opens a strategic entry point into one of the world’s largest dermatology markets, where premium topical products command strong pricing power. Early‑stage launch planning suggests a focus on dermatology clinics and hospital pharmacies, leveraging the company’s existing distribution network. Success in China could boost global sales, reinforce LEO’s psoriasis portfolio, and signal confidence for future submissions of other pipeline assets in the region, underscoring the broader trend of multinational pharma firms capitalising on China’s evolving regulatory landscape.